Transparencia

Transparency and Government Funding

Candel SpA is a medical technology company specialized in non-invasive neuromodulation, headquartered in Santiago, Chile and Davis, California. In compliance with Law N° 21.722 (Public Sector Budget Law), we openly publish our institutional report and the detail of resources received from public agencies.

Institutional Report 2025

During 2025, Candel SpA consolidated its position as a reference in neurological rehabilitation technology in Latin America. This document contains the institutional report for the year 2025.

Public Resources Received

The following table details all resources received from public agencies, in compliance with Law N° 21.722.

Date Amount Granting Agency
01/09/2022 $10.000.000 CORFO / Start-Up Chile, Build 4 (22BLD-212024)
02/01/2024 $25.000.000 CORFO / Start-Up Chile, Ignite 6 (23IGN-242798)
02/08/2024 $134.516.880 Ministerio de Ciencia, Tecnología, Conocimiento e Innovación – StartUp Ciencia 2024 (SUC240058)
19/11/2025 $66.722.209 CORFO – Crea y Valida 2025 (25CVI-302421)

* Includes all resources received from public agencies (CORFO, ANID or others). Private financing projects are not detailed in this record.

Board of Directors / Senior Management Body

RUT First Name(s) Surname(s)
19465396-4 Raúl Sebastián Castillo Astorga
19492009-1 Sebastián Andrés Muena Cortés

Main Administrators

RUT First Name(s) Surname(s)
19465396-4 Raúl Sebastián Castillo Astorga
19492009-1 Sebastián Andrés Muena Cortés

Full Document

You can download the full institutional report in PDF format:

Download PDF – Institutional Report 2025

Best-selling

What is tDCS?

Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation (NIBS) technique. It is based on the controlled application of a low-intensity electrical current, vibrating between 1 and 2 milliamperes (mA), through the placement of two electrodes, one anodal and one cathodal, on the surface of the brain. tDCS is an emerging therapy for neurological conditions.

Scientific evidence of tDCS

Combined therapy of bilateral transcranial direct current stimulation and ocular occlusion improves visual function in adults with amblyopia, a randomized pilot study

 More information here

The effects of transcranial direct-current stimulation (tDCS) on pain intensity of patients with fibromyalgia: a systematic review and meta-analysis

 More information here

Early transcranial direct current stimulation with modified constraint-induced movement therapy for motor and functional upper limb recovery in hospitalized patients with stroke: A randomized, multicentre, double-blind, clinical trial.

 More information here

Our commitment to patient well-being

At Candel, we are dedicated to providing safe and quality rehabilitation, accessible to all. With cutting-edge medical technology, we work tirelessly to develop innovations that will improve the future of neurology, ensuring that every patient receives the best possible care.

We are on Mercado Público!

We are the only national company that commercializes neurostimulators in Mercado Público, facilitating access to advanced technology for neurological rehabilitation.

OUR

SPECIALISTS

Raúl Castillo

Physician from the University of Chile. PhD candidate in Biomedical Engineering at the University of California, Davis. Founder and CEO.

Lucía Del Valle

MD from the University of Chile. PhD candidate in Medical Sciences and specialist in Neurology from the University of Chile. Co-founder and CSO.

OUR ADVISORS

Prof. Dr. Nigel Pedersen

Neurologist and Epileptologist. Associate Professor and Director of Research, Department of Neurology, UC Davis. Scientific and Medical Advisor.

Prof. Dr. Rómulo Fuentes Flores

Mentor and Technical-Scientific Advisor. Director of Research at the Faculty of Medicine, University of Chile.

Prof. Dr. José Manuel Matamala

Neurologist at Clínica Alemana - PhD in Medical Sciences. Scientific and Medical Advisor.
crea una imagen de invvestigadores/neurologos

FOR RESEARCHERS

At Candel Medical Company, we support the development of clinical and scientific research in neuromodulation technologies.

Our Researchers Program is designed to facilitate access to technology, offer preferential conditions, and support projects seeking to generate evidence and advance innovation in healthcare.

If you are conducting research or have a project in the planning stage, we would like to hear from you.

Contact us at: contacto@candelmed.cl

Subject: Researchers Program